Last checked at UK EXECUTIVE CHANGE SUMMARY: New Chairs For Matomy And Shield
UK EXECUTIVE CHANGE SUMMARY: New Chairs For Matomy And Shield
26 May 20 14:22
- Home
- Share Prices
- NEX Exchange Share Prices
- Share Chat
- FX
- News
- Blogs
- RNS
- Media
- Trading
- Finance Tools
- Members
Latest Share Chat
Shield Thera Share News (STX)
STX Share
Price
STX Share
News
STX Share
Chat1
STX Share
Trades14
STX
Live RNS
STX Share
Charts
STX Level 2
Console
STX Live
Share Price
STX Broker
Ratings
STX Directors
Deals
STX Financial
Diary
STX
Fundamentals
STX Short
Positions
STX
Media
STX Information
Share Price Information for Shield Thera (STX)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
98.50
Bid:
95.00
Ask:
102.00
Change:
-2.50
(-2.48%)
Spread:
7.00 (7.37%)
Open:
101.00
High:
101.00
Low:
98.50
Yest. Close:
101.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.26 May 20 14:22Shield Therapeutics names Hans Peter Hasler as next chairman
(Sharecast News) - Pharmaceutical group Shield Therapeutics named Hans Peter Hasler as non-executive chairman of the company on Tuesday.
26 May 20 08:58UK TRADING UPDATE SUMMARY: Avacta, Genedrive Progress With Virus Tests
UK TRADING UPDATE SUMMARY: Avacta, Genedrive Progress With Virus Tests
1 May 20 13:28Shield Therapeutics FY revenues impacted by milestone repayment
(Sharecast News) - Pharmaceuticals outfit Shield Therapeutics warned on Friday that full-year revenues would be lower than originally anticipated after it had to repay a sizeable milestone payment.
1 May 20 09:55UK EXECUTIVE CHANGE SUMMARY: Shield Therapeutics Replaces Founder
UK EXECUTIVE CHANGE SUMMARY: Shield Therapeutics Replaces Founder
22 Apr 20 15:13Shield Therapeutics Starts Independent Review Into Feraccru Study
Shield Therapeutics Starts Independent Review Into Feraccru Study
18 Mar 20 07:33Shield launches review after spotting flaw in 'Feraccru' study
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics updated the market on the 'AEGIS-H2H' clinical trial on Tuesday, the data of which was primarily designed to be used in health economic analyses, pricing and reimbursement applications, as well as marketing purposes.
17 Mar 20 15:17Shield Therapeutics 2019 Revenue To Drop But Will Meet Expectations
Shield Therapeutics 2019 Revenue To Drop But Will Meet Expectations
27 Jan 20 15:07Shield Therapeutics details year of 'material progress'
(Sharecast News) - Drugs developer Shield Therapeutics told investors on Monday that 2019 had been a year of "material progress", with a key success being the recent Federal Drug Administration approval of its iron deficiency treatment, Feraccru/Accrufer.
27 Jan 20 08:09Shield Therapeutics Gets China Licence Agreement For Feraccru/Accrufer
Shield Therapeutics Gets China Licence Agreement For Feraccru/Accrufer
8 Jan 20 09:45DIRECTOR DEALINGS: Shield Therapeutics Chair Buys GBP134,000 In Shares
(Alliance News) - Shield Therapeutics PLC on Thursday said Chair James Karis acquired shares in the pharmaceutical company following a transaction on Tuesday.Karis purchased 75,000 shares a
15 Aug 19 14:28Shield Therapeutics Narrows Interim Losses Amid Expenses Fall
(Alliance News) - Drugmaker Shield Therapeutics said on Wednesday a payment from a commercial partner contributed to a sharp revenue rise in the first half of the year.In the six months to
7 Aug 19 12:02Teva Appeals Shield Therapeutics European Drug Patent Win
LONDON (Alliance News) - Shield Therapeutics PLC on Monday said Israeli pharmaceutical company Teva Pharmaceutical Industries Ltd has filed a notice of appeal on a decision regarding a Shield in a
3 Jun 19 10:27DIRECTOR DEALINGS: Shield Therapeutics Medical Chief Buys Shares
LONDON (Alliance News) - Shield Therapeutics PLC said on Friday that Chief Medical Officer Mark Sampson and his wife Julia have purchased shares in the company on Thursday.Mark bought at a
26 Apr 19 18:19Shield Therapeutics' Feraccru Granted Use Extension In Switzerland
LONDON (Alliance News) - Shield Therapeutics PLC said on Wednesday said the Swiss Agency for Therapeutic Products has approved the Feraccru product to treat iron deficiency in adults with or is to
24 Apr 19 12:22